Dopamine d₁-like receptors suppress proliferation of vascular smooth muscle cell induced by insulin-like growth factor-1

References

• Lacolley P, Regnault V, Nicoletti A, et al. The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles. Cardiovasc Res 2012;95:194–204
   PubMed Web of Science ®Google Scholar
• Wu X, Cheng J, Li P, et al. Mechano-sensitive transcriptional factor Egr-1 regulates insulin-like growth factor-1 receptor expression and contributes to neointima formation in vein grafts. Arterioscler Thromb Vasc Biol 2010;30:471–6
   PubMed Web of Science ®Google Scholar
• Radhakrishnan Y, Busby WH Jr, Shen X, et al. Insulin-like growth factor-I-stimulated insulin receptor substrate-1 negatively regulates Src homology 2 domain-containing protein-tyrosine phosphatase substrate-1 function in vascular smooth muscle cells. J Biol Chem 2010;285:15682–95
   PubMed Web of Science ®Google Scholar
• Furundzija V, Fritzsche J, Kaufmann J, et al. IGF-1 increases macrophage motility via PKC/p38-dependent alphavbeta3-integrin inside-out signaling. Biochem Biophys Res Commun 2010;394:786–91
   PubMed Web of Science ®Google Scholar
• Delafontaine P, Song YH, Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol 2004;24:435–44
   PubMed Web of Science ®Google Scholar
• Allen TR, Krueger KD, Hunter WJ III, et al. Evidence that insulin-like growth factor-1 requires protein kinase C-epsilon, PI3-kinase and mitogen-activated protein kinase pathways to protect human vascular smooth muscle cells from apoptosis. Immunol Cell Biol 2005;83:651–67
   PubMed Web of Science ®Google Scholar
• Zeng C, Armando I, Luo Y, et al. Dysregulation of dopamine-dependent mechanisms as a determinant of hypertension: studies in dopamine receptor knockout mice. Am J Physiol Heart Circ Physiol 2008;294:H551–69
   PubMed Web of Science ®Google Scholar
• Zeng C, Zhang M, Asico LD, et al. The dopaminergic system in hypertension. Clin Sci 2007;112:583–97
   PubMed Web of Science ®Google Scholar
• Yasunari K, Kohno M, Hasuma T, et al. Dopamine as a novel antimigration and antiproliferative factor of vascular smooth muscle cells through dopamine D1-like receptors. Arterioscler Thromb Vasc Biol 1997;17:3164–73
   PubMed Web of Science ®Google Scholar
• O’Connell DP, Vaughan CJ, Aherne AM, et al. Expression of the dopamine D3 receptor protein in the rat kidney. Hypertension 1998;32:886–95
   PubMed Web of Science ®Google Scholar
• Ozono R, O’Connell DP, Wang ZQ, et al. Localization of the dopamine D1 receptor protein in the human heart and kidney. Hypertension 1997;30:725–9
   PubMed Web of Science ®Google Scholar
• Zeng C, Wang D, Yang Z, et al. D1 dopamine receptor augmentation of D3 receptor action in rat aortic or mesenteric vascular smooth muscles. Hypertension 2004;43:673–9
   PubMed Web of Science ®Google Scholar
• Li Z, Yu C, Han Y, et al. Inhibitory effect of D1-like and D3 dopamine receptors on norepinephrine-induced proliferation in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2008;294:H2761–8
   PubMed Web of Science ®Google Scholar
• Huang H, Han Y, Wang X, et al. Inhibitory effect of the D(3) dopamine receptor on insulin receptor expression and function in vascular smooth muscle cells. Am J Hypertens 2011;24:654–60
   PubMed Web of Science ®Google Scholar
• Zeng C, Han Y, Huang H, et al. D1-like receptors inhibit insulin-induced vascular smooth muscle cell proliferation via down-regulation of insulin receptor expression. J Hypertens 2009;27:1033–41
   PubMed Web of Science ®Google Scholar
• Arnqvist HJ, Bornfeldt KE, Chen Y, et al. The insulin-like growth factor system in vascular smooth muscle: interaction with insulin and growth factors. Metabolism 1995;44:58–66
   PubMed Web of Science ®Google Scholar
• Johansson GS, Arnqvist HJ. Insulin and IGF-I action on insulin receptors, IGF-I receptors, and hybrid insulin/IGF-I receptors in vascular smooth muscle cells. Am J Physiol Endocrinol Metab 2006;291:E1124–30
   PubMed Web of Science ®Google Scholar
• Zeng C, Liu Y, Wang Z, et al. Activation of D3 dopamine receptor decreases angiotensin II type 1 receptor expression in rat renal proximal tubule cells. Circ Res 2006;99:494–500
   PubMed Web of Science ®Google Scholar
• Sanada H, Asico LD, Shigetomi S, et al. The effect of docarpamine, a dopamine pro-drug, on blood pressure and catecholamine levels in spontaneously hypertensive rats. Clin Exp Hypertens 2000;22:419–29
   PubMed Web of Science ®Google Scholar
• Lin H, Lee JL, Hou HH, et al. Molecular mechanisms of the antiproliferative effect of beraprost, a prostacyclin agonist, in murine vascular smooth muscle cells. J Cell Physiol 2008;214:434–41
   PubMed Web of Science ®Google Scholar
• Yasunari K, Kohno M, Kano H, et al. Dopamine as a novel antioxidative agent for rat vascular smooth muscle cells through dopamine D(1)-like receptors. Circulation 2000;101:2302–8
   PubMed Web of Science ®Google Scholar
• Yasunari K, Maeda K, Nakamura M, et al. Dopamine as a novel anti-migration factor of vascular smooth muscle cells through D1A and D1B receptors. J Cardiovasc Pharmacol 2003;1:S33–8
   Google Scholar
• Dalby B, Cates S, Harris A, et al. Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications. Methods 2004;33:95–103
   PubMed Web of Science ®Google Scholar
• Bolster DR, Crozier SJ, Kimball SR, et al. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem 2002;277:23977–80
   PubMed Web of Science ®Google Scholar
• Corradetti MN, Guan KL. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene 2006;25:6347–60
   PubMed Web of Science ®Google Scholar
• Higashi Y, Sukhanov S, Anwar A, et al. Aging, atherosclerosis, and IGF-1. J Gerontol A Biol Sci Med Sci 2012;67:626–39
   Google Scholar
• Nolan BP, Senechal P, Waqar S, et al. Altered insulin-like growth factor-1 and nitric oxide sensitivities in hypertension contribute to vascular hyperplasia. Am J Hypertens 2003;16:393–400
   PubMed Web of Science ®Google Scholar
• Lim HJ, Park HY, Ko YG, et al. Dominant negative insulin-like growth factor-1 receptor inhibits neointimal formation through suppression of vascular smooth muscle cell migration and proliferation, and induction of apoptosis. Biochem Biophys Res Commun 2004;325:1106–14
   PubMed Web of Science ®Google Scholar
• Jia G, Cheng G, Agrawal DK. Differential effects of insulin-like growth factor-1 and atheroma-associated cytokines on cell proliferation and apoptosis in plaque smooth muscle cells of symptomatic and asymptomatic patients with carotid stenosis. Immunol Cell Biol 2006;84:422–9
   PubMed Web of Science ®Google Scholar
• Díez J. Insulin-like growth factor I in essential hypertension. Kidney Int 1999;55:744–59
   PubMed Web of Science ®Google Scholar
• Marwaha A, Lokhandwala MF. Diminished natriuretic response to dopamine D1 receptor agonist, SKF-38393 in obese Zucker rats. Clin Exp Hypertens 2003;25:509–15
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cincotta AH. Inhibitory effects of bromocriptine on vascular smooth muscle cell proliferation. Atherosclerosis 1997;133:37–44
   PubMed Web of Science ®Google Scholar
• LeRoith D, Werner H, Beitner-Johnson D, et al. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995;16:143–63
   PubMed Web of Science ®Google Scholar
• Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3–34
   PubMed Web of Science ®Google Scholar
• Johansson GS, Arnqvist HJ. Insulin and IGF-I action on insulin receptors, IGF-I receptors, and hybrid insulin/IGF-I receptors in vascular smooth muscle cells. Am J Physiol Endocrinol Metab 2006;291:E1124–30
   PubMed Web of Science ®Google Scholar